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Abstract Interleukin-6 (IL-6) is the major activator of
the acute phase response (APR). One important regulator
of IL-6-activated APR is peroxisome proliferator-activated
receptor alpha (PPARa). Currently, there is a growing
interest in determining the role of PPARa in regulating
APR; however, studies on the molecular mechanisms and
signaling pathways implicated in mediating the effects of
IL-6 on the expression of PPARa are limited. We previ-
ously revealed that IL-6 inhibits PPARa gene expression
through CAAT/enhancer-binding protein transcription
factors in hepatocytes. In this study, we determined that
STAT1/3 was the direct downstream molecules that med-
iated the Janus kinase 2 (JAK2) and phosphatidylinositol-3
kinase (PI3K)/AKT/mammalian target of rapamycin
(mTOR) signaling pathways in IL-6-induced repression of
PPARa. Treatment of cells with pharmacological inhibitors
of JAK2, PI3K, AKT, and mTOR attenuated the inhibitory
effect of IL-6 on PPARa protein in a dose-dependent
manner. These inhibitors also decreased the IL-6-induced
repression of PPARa mRNA expression and promoter
activity. Overexpression of STAT1 and STAT3 in HepG2
cells cotransfected with a reporter vector containing this
PPARa promoter region revealed that both the expression
plasmids inhibited the IL-6-induced repression of PPARa
promoter activity. In the presence of inhibitors of JAK2
and mTOR (AG490 and rapamycin, respectively), IL-6-
regulated protein expression and DNA binding of STAT1
and STAT3 were either completely or partially inhibited
simultaneously, and the IL-6-induced repression of PPARa
protein and mRNA was also inhibited. This study has
unraveled novel pathways by which IL-6 inhibits PPARa
gene transcription, involving the modulation of JAK2/
STAT1–3 and PI3K/AKT/mTOR by inducing the binding
of STAT1 and STAT3 to STAT-binding sites on the
PPARa promoter. Together, these findings represent a new
model of IL-6-induced suppression of PPARa expression
by inducing STAT1 and STAT3 phosphorylation and
subsequent down-regulation of PPARa mRNA expression.
Keywords Acute phase response  Interleukin-6 
Peroxisome proliferator alpha  Cell signaling
pathways  Human HepG2 hepatocyte cells
Introduction
Organisms respond toward changes in local or systemic
disturbances in homeostasis caused by infection, injury,
and trauma by triggering a highly complicated but precise
gene regulation network. Acute phase response (APR) is
one of the major reactions initiated in human liver to
restore disturbed homeostasis to normal physiological
levels [1–3]. APR mediates changes in the concentration of
plasma proteins known as acute phase proteins (APPs)
which act as effectors of APR [4–6]. APPs are modulated
positively or negatively by cytokines especially interleu-
kin-6 (IL-6) mainly by altering the rate of their synthesis in
the liver [7–9]. The onset of APR triggered by IL-6 may
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lead to local inflammation in cancer, atherosclerosis, and
infection of hepatic origin [10–13].
IL-6 belongs to a family which includes IL-11, IL-27,
ciliary neurotropic factor, oncostatin M, leukemia inhibi-
tory factor, cardiotrophin-1, cardiotrophin-like cytokine,
and neurotrophin. IL-6 is a typical pleiotropic cytokine that
plays a pivotal role in the immune and the hematopoietic
system, as well as various physiological events such as cell
proliferation and differentiation [14, 15]. IL-6 was first
demonstrated to be the major inducer of APPs in primary
cultures of human hepatocytes where it induced the syn-
thesis of C-reactive protein (CRP) and serum amyloid A
(SAA) [16]. Subsequently, studies using human liver cell
lines such as HepG2 showed that the gene expression of
other APPs including fibrinogen, a1-antichymotrypsin,
ceruloplasmin, haptoglobin, a1-acid glycoprotein (gp), and
a1-antitrypsin is also modulated by IL-6 [17–19].
Many studies have reported the role of transcription
factors in mediating the action of cytokines in modulating
gene expression of APPs such as members of CAAT/
enhancer-binding proteins (C/EBPs) and hepatocyte
nuclear factors HNF-1, HNF-3, HNF-4, and HNF-6 [20–
22]. There is also evidence indicating the transcriptional
regulation of APPs by a member of ligand-activated
nuclear hormone receptors, peroxisome proliferator acti-
vator receptor alpha (PPARa). PPARa which is highly
expressed in hepatocytes, skeletal muscle, cardiomyocytes,
and brown adipose tissues, regulates cholesterol homeo-
stasis and fatty acid catabolism [23–25]. In mice treated
with the PPARa agonist, fenofibrate, the actions of IL-6 on
modulation of gene expression on APPs are suppressed.
Furthermore, this proved that the effect of PPARa prevents
the IL-6-induced expression of the APR genes via PPARa-
dependent mechanisms, directly at the transcriptional level
[26]. Studies also demonstrated that regulation of PPARa
expression is of crucial importance not only in the devel-
opment of the APR in liver, but also in inflammation and
atherosclerosis [25–29]. The signal transduction cascades
represent a complex regulatory network in processes of
diseases and may provide a common target for therapeutic
intervention. At present, the IL-6 signaling pathway in the
regulation of PPARa during APR is poorly understood.
Although the expression of PPARa has been found to be
down-regulated by cytokines during physiological and
pathophysiological changes [30–33], studies to determine
the action of IL-6 on PPARa gene expression in liver cells
are limited. Recently, we reported that IL-6 decreased
PPARa mRNA expression, and this was mediated by
C/EBP members [20]. However, the mechanisms of IL-6
and IL-6 receptor-mediated signaling in liver cells on
PPARa expression and APR have not been fully explored.
In this study, we demonstrated that Janus kinase 2
(JAK2)–STAT1–3 and phosphatidylinositol-3 kinase
(PI3K) pathways were involved in IL-6-induced suppres-
sion of PPARa expression. Furthermore, our results also
suggest that IL-6-induced STAT1 and STAT3 proteins
were essential for mediating the IL-6-inhibitory action on
PPARa gene expression in human hepatocarcinoma
HepG2 cells.
Materials and methods
Materials
The recombinant human IL-6 was obtained from National
Institute for Biological Standards and Control, UK. Human
HepG2 cell line was purchased from American Type
Culture Collection. All cell culture reagents were pur-
chased from Gibco/BRL. Rabbit polyclonal antibodies
directed against the STAT1, STAT3, PI3K, AKT, mam-
malian target of rapamycin (mTOR), PPARa, b-actin; and
the phosphorylated forms Tyr701 STAT1, Tyr705 STAT3,
Ser727 STAT1, Ser727 STAT3, Tyr458/199 PI3K, Tyr30 AKT,
and Ser2448 mTOR were purchased from Cell Signaling
Technology (Beverly, MA, USA). Pharmacological inhib-
itors, AG490, were purchased from Tocris Bioscience (St.
Louis, MO, USA); wortmannin and AKT were obtained
from Calbiochem (Pacific Center Court, San Diego, CA,
USA); and rapamycin was purchased from Sigma-Aldrich
(St. Louis, MO, USA).
Cell culture and IL-6 treatment
HepG2 cell lines were cultured in MEM supplemented
with 10 % (v/v) heat-inactivated fetal bovine serum (HI-
FBS), 100 U/ml penicillin, and 100 lg/ml streptomycin.
The cells were maintained at 37 C in a humidified
atmosphere with 5 % (v/v) CO2. Before treatment with
1,000 U/ml of IL-6 or various inhibitors against compo-
nents of signal transduction pathways, the cells were pre-
incubated in reduced concentration of HI-FBS (0.5 %) for
4 h [34].
Real-time RT-PCR
Total cellular RNA was isolated from HepG2 cell line
using Tri-Reagent LS (Molecular Research Center)
according to the manufacturer’s instructions. Real-time
RT-PCR was performed using iScript One-Step RT-PCR
Kit with SYBR Green (Bio-Rad) [20]. In brief, the reaction
contained 600 ng of DNase-treated RNA isolated from
HepG2 cells, 15 ll of 29 SYBR Green RT-PCR Reaction
Mix, 1 ll of each forward and reverse primers (10 ll), and
1 ll of iScript Reverse Transcriptase in a final volume of
30 ll. Real-time PCR was performed in a iCycler iQ
R
E
V
IS
E
D
PR
O
O
F
Multicolor Real-Time PCR Detection System (Bio-Rad).
The program consisted of 1 cycle each of 20 min at 50 C
and 5 min at 95 C, followed by 30 cycles of denaturing at
95 C for 15 s; annealing at 60 C for 20 s; and primer
extension at 72 C for 30 s. The quantity of PPARa mRNA
was normalized against the b-actin housekeeping gene as
previously described [20].
SDS-PAGE and western blot analysis
Total cellular protein was isolated using NE-PER Nuclear
and Cytoplasmic Extraction Reagents (Pierce) following
the manufacturer’s instructions. The cytoplasmic extracts
were prepared from control and treated cells. 100 and
30 lg of proteins were used in SDS-PAGE to determine
the levels of protein content for phosphorylated Tyr701
STAT1, Tyr705 STAT3, Ser727 STAT1, Ser727 STAT3,
Tyr458/199 PI3K, Tyr30 AKT, and Ser2448 mTOR; and for
PPARa and b-actin, respectively. Subsequently, proteins
were transferred to a polyvinylidene difluoride membrane
(Millipore) and incubated with blocking solution [19 PBS
containing 5 % (w/v) skimmed milk powder and 0.1 % (v/
v) Tween-20] for 1 h at room temperature by shaking. The
membrane was washed three times for 10 min each in
washing solution [19 PBS and 0.1 % (v/v) Tween-20] and
incubated with primary antibodies (rabbit anti-human
Tyr701 STAT1, Tyr705 STAT3, Ser727 STAT1, Ser727
STAT3, Tyr458/199 PI3K, Tyr30 AKT, Ser2448 mTOR,
PPARa, and b-actin), which was diluted 1/1,000 in 19
PBS containing 1 % (w/v) skimmed milk powder and
0.1 % (v/v) Tween-20, for 1 h at room temperature. The
membrane was then washed and immersed in secondary
antibody (peroxidase-conjugated goat anti-rabbit IgG)
diluted 1/2,000 in 19 PBS containing 1 % (w/v) skimmed
milk powder and 0.1 % (v/v) Tween-20. Detection of
membrane-bound antigen–antibody complexes was carried
out as per the instructions provided with the ECL kit (GE
Healthcare) and Fuji Medical X-ray film. WestviewTM
Western Size Marker (Mbiotech, Inc., Songpagu, Seoul)
and immunoreactive proteins were visualized on X-ray
film.
Electrophoretic mobility shift assay (EMSA)
and antibody supershift assay
Nuclear extracts were extracted using NE-PER Nuclear and
Cytoplasmic Extraction Reagents (Pierce). The sequences of
the oligonucleotides containing the STAT-binding site (-612
to -604; [20]) were 50-AGAATTCTTCCTCCAAGAGTTA-
30 and 50-TAACTCTTGGAGGAAGAATTCT-30. The oli-
gonucleotides were labeled using biotin 30-End DNA Label-
ing kit (Pierce) according to manufacturer’s instructions. For
binding reactions, 20 lg of nuclear extracts were incubated
with labeled oligonucleotides using LightShift Chemilumi-
nescent EMSA kit (Pierce) according to manufacturer’s
instructions. DNA–protein complexes were then resolved by
electrophoresis using 6 % (w/v) nondenaturing polyacryl-
amide gels (29:1, acrylamide:bisacrylamide). DNA–protein
complexes were transferred to nylon membranes (Hybond
N?), and subsequently, detection of the biotin-labeled DNA
was carried out using a Fuji Medical X-ray film. For antibody
supershift (SS) assays, 1 ll of STAT1 or STAT3 antibody
(Cell Signaling) was mixed with the binding reactions, and the
mixture was incubated on ice for 20 min followed by 20 min
at room temperature before the labeled oligonucleotides were
added.
PPARa promoter–reporter plasmids
The construction of human PPARa promoter -765/?34 in
pGL3-Basic Vector was described previously [20]. The
PPARa promoter -765/?34 was mutated at positions -607,
-608, and -610 within the STAT recognition element (nucle-
otides -612 to -604) using the QuickChangeTM Site-Directed
Mutagenesis Kit (Stratagene). The sample reaction consisted of
19 reaction buffer, 50 ng double-stranded DNA template, and
125 ng of complimentary oligonucleotides [50-CAAGAATT
CTTGCCACAAGAGTTACAG-GTCAGT-30 and 50-ACT
GACCTGTAACTCTTGTGGcAAGAATTCTTG-30] of the
human PPARa promoter. The mutated construct was desig-
nated as STATmut PPARa promoter. The change in sequence
was confirmed by DNA sequencing.
Transient transfection assays
HepG2 cells were transfected with plasmids using lipo-
fectin transfection reagent (Invitrogen Life Technologies)
according to manufacturer’s instruction with slight modi-
fication as previously described [20, 34]. Cells were
replated 12 h before transfection at a density of 9 9 105
cells in 2 ml of fresh culture medium in a six-well plastic
dish. The cells were transfected with 2 lg of wild-type (wt)
PPARa promoter luciferase construct or the STATmut
PPARa promoter luciferase construct and 0.5 lg thymidine
kinase/Renilla (pRL-TK) vector as a control for transfec-
tion efficiency. For the over expression studies, HepG2
cells were cotransfected with 2 lg of PPARa promoter
luciferase construct, 0.5 lg pRL-TK plasmid, and either 2
lg of STAT1 or STAT3 expression plasmids or 2 lg of
empty vector. Following transfection, cells were treated
and then harvested for analysis for firefly luciferase and
Renilla luciferase activities using the Dual Luciferase
Reporter Assay System (Promega). Relative light units
were determined by dividing firefly luciferase activity by
Renilla luciferase activity. Results are given as an average
of three independent assays ± SD.
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Assay of luciferase activity
Luciferase activity was measured by means of the lucif-
erase assay system. Transfected cells grown in six-well
plastic dishes were washed with PBS and lysed, each with
500 ll of passive lysis buffer per well. Luciferase activity
was determined as instructed by the manufacturer (Pro-
mega). In brief, 20 ll of cell extracts were mixed at room
temperature with 100 ll of Luciferase Assay Buffer II,
LARII (Promega), and measurements were read in a
luminometer (TD-20/20 Turner Designs, CA, USA). Re-
nilla luciferase was used as an internal control for trans-
fection efficiency.
Statistical analysis
Statistical analysis was determined using one-way analysis
of variation (ANOVA) or paired t test available in
GraphPad Prism Version 3.02 software. P \ 0.05 was
considered to be statistically significant, P \ 0.01 very
significant and P \ 0.001 highly significant.
Results
IL-6 activates the components of JAK/STAT and PI3K
signal transduction pathways in HepG2 cells
IL-6 has been shown to regulate target genes via the acti-
vation of the JAK/STAT and PI3K pathways in hepato-
cytes [35, 36]. However, studies investigating the action of
IL-6 phosphorylation of the components of JAK–STAT
and PI3K pathways in HepG2 cells are limited. Western
blot analysis showed that the treatment of HepG2 cells with
IL-6 over a period of 60 min produced a marked increase
in the level of phosphorylation of STAT1 Tyr701 and
STAT3 Tyr705 within 15–30 min but not the total STAT1
and STAT3 (Fig. 1a). The levels of phosphorylated STAT1
Ser727 and STAT3 Ser727 were also increased after
15–30 min treatment with IL-6 albeit at lower levels.
For the components of the PI3K signaling pathway,
treatment of HepG2 cells with IL-6 over a period of
240 min produced a dose-dependent response on the levels
of phosphorylated PI3K Tyr458/199, AKT Tyr30, and mTOR
Ser2448 (Fig. 1a). In all cases, the levels of phosphorylated
proteins were increased after 15 min, sustained at 30 min,
and gradually decreased thereafter. The total protein levels
of PI3K, AKT, and mTOR remained unchanged.
In order to corroborate that JAK/STAT and PI3K
pathways were activated in response to IL-6 treatment,
various concentrations of pharmacological inhibitors
against the identified signaling proteins were used to
preincubate the cells for 2 h, followed by IL-6 treatment
for requisite time. AG490, a JAK inhibitor, was used to
identify the JAK–STAT pathway [37–40], and the wort-
mannin, AKTIV, and rapamycin inhibitors were used,
respectively, to identify the PI3K, AKT, and mTOR com-
ponents in the PI3K pathway [41, 42]. AG490 inhibited the
IL-6-induced phosphorylation of STAT1 (Tyr705) and
STAT3 (Tyr705) in a dose-dependent manner (Fig. 1b).
In delineating the PI3K pathway, we discovered that
wortmannin was able to attenuate the phosphorylation of
AKT, a downstream component of PI3K pathway. In
addition, AKTIV inhibitor at a concentration of 0.5 lM
abolished the IL-6-induced phosphorylation of mTOR,
another downstream component of PI3K pathway
(Fig. 1b).
In order to delineate the existence of crosstalk between
JAK–STAT and PI3K pathways in IL-6-treated HepG2
cells, rapamycin and AG490 were used to pretreat cells
followed by incubation using IL-6 for requisite time.
Subsequently, the levels of phosphorylated PI3K, STAT1,
and STAT3 were determined, respectively. IL-6-mediated
induction of the phosphorylated STAT1 and STAT3 was
slightly inhibited by rapamycin (Fig. 1c). Similarly, the
attenuated effect of AG490 was also observed on the IL-6-
induced phosphorylation of PI3K, albeit at relatively lower
levels than the effect of AG490 on STAT phosphorylation.
Based on these results, PI3K/AKT/mTOR pathway may
play a minor role in the activation of JAK–STAT pathway,
and vice versa.
IL-6-inhibitory effects on PPARa mRNA expression
are mediated by JAK–STAT and PI3K signal
transduction pathways
Previously, we showed that IL-6 down-regulated the
expression of PPARa at the levels of mRNA, protein
content, and binding activity [20]. Having established that
IL-6 mediated its cellular effect on HepG2 via JAK–STAT
and PI3K/AKT/mTOR pathways (Fig. 1), we next exam-
ined whether these pathways were involved in mediating
the inhibitory action of IL-6 on PPARa gene expression.
We examined the effects of JAK–STAT and PI3K inhibi-
tors on IL-6-inhibitory action on PPARa protein content.
The inhibitors dose dependently inhibited the IL-6-sup-
pressed PPARa protein expression (Fig. 2a). AG490 pro-
duced a statistically significant inhibition on the action of
IL-6 with the highest level at 500 lM, and its levels of
protein content were increased by 38 % compared with IL-
6-treated HepG2 cells that were not preincubated with the
inhibitor. Similarly, the inhibitory effect of IL-6 on PPARa
protein content was significantly attenuated by wortman-
nin, AKTIV, and rapamycin with the highest levels being
achieved at 4 mM (28 %), 1 mM (32 %), and 2 mM
(38 %), respectively.
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To determine if the same inhibitors also attenuated the
inhibitory action of IL-6 on PPARa mRNA levels, real-
time PCR was performed on RNA isolated from IL-6-
treated HepG2 cells preincubated with the inhibitors
against JAK–STAT and PI3K/AKT/mTOR pathways.
Messenger RNA expression of PPARa was decreased to
approximately 50 % of that of the control in the presence
of 1,000 U/ml of IL-6 (Fig. 2b), which is consistent with
our previous study [20]. Treatment of HepG2 cells with
1,000 U/ml IL-6 was significantly attenuated by the
inhibitors in suppressing PPARa mRNA levels which also
correspond with the protein content. AG490, wortmannin,
Fig. 1 IL-6 activated the components of JAK/STAT and PI3K signal
transduction pathways in HepG2 cells. a Time-dependent effect of IL-
6 on STAT1 and STAT3, PI3K, AKT, and mTOR activation. Western
blotting was used to detect for phosphorylated form of STAT1 and
STAT3, PI3K, AKT, mTOR and their total STAT1 and STAT3,
PI3K, AKT, and mTOR proteins, respectively. b Concentration-
dependent inhibition of pharmacological inhibitors on their target
proteins at the upstream to delineate downstream proteins. Cells were
pretreated with various concentrations of inhibitors for STAT1 and
STAT3, PI3K, AKT, and mTOR for 2 h, followed by stimulation with
1,000 U/ml for 15 min for STAT1 and STAT3, 30 min for AKT and
45 min for mTOR, respectively. Western blot was used to detect for
STAT1 and phosphorylated form of STAT1, STAT3 and phosphor-
ylated form of STAT3, AKT and phosphorylated form of AKT and
mTOR and phosphorylated form of mTOR. c Rapamycin and AG490
were used to pretreat the cells followed by incubation with IL-6 for
requisite time to determine the levels of phosphorylated STAT1 and
STAT3, and phosphorylated form of PI3K, respectively, in delineat-
ing the crosstalk between JAK–STAT and PI3K pathways
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AKTIV, and rapamycin increased the levels of PPARa
mRNA by 50, 35, 22, and 30 %, respectively, compared
with IL-6-treated cells in the absence of inhibitors
(Fig. 2b).
These results showed that the inhibitors abolished the
inhibitory action of IL-6 on PPARa gene expression both
at the mRNA and protein level. Taken together, the results
suggest that JAK2–STAT1/3 and PI3K/AKT/mTOR path-
ways are involved in IL-6-induced PPARa suppression in
HepG2 cells.
JAK/STAT and PI3K pathways are involved in IL-6-
induced suppression on PPARa promoter activity
Previously, we demonstrated that the human PPARa pro-
moter construct region from -765 to ?34 displayed an
approximately 50 % decrease in luciferase activity in
HepG2 cells treated with IL-6, indicating that the IL-6
down-regulated the PPARa mRNA expression at the levels
of transcription [20]. Since IL-6 decreased PPARa mRNA
and protein via JAK2–STAT1/3 and PI3K/AKT/mTOR
pathways, we investigated the role of similar pathways in
modulating the PPARa promoter activity by means of
pharmacological inhibitors against the identified compo-
nents of signaling pathways.
In order to confirm the JAK2–STAT1/3 inhibition
effects on the action of IL-6 in down-regulating PPARa
transcriptional activity, HepG2 cells were preincubated
with 500 lM AG490 for 2 h followed immediately by IL-6
treatment for 24 h on PPARa promoter transiently trans-
fected cells. In agreement with our previous study [20], the
activity from wt PPARa promoter was reduced by 50 %
Fig. 2 IL-6-inhibitory effects
on PPARa mRNA and protein
expression are mediated by
JAK–STAT and PI3K
pathways. a Dose-dependent
inhibition of AG490,
wortmannin, AKTIV, and
rapamycin on IL-6-induced
repression of PPARa protein.
b The effects of AG490,
wortmannin, AKTIV, and
rapamycin on IL-6-mediated
suppression of PPARa mRNA.
Total cellular RNA was isolated
and subjected to real-time PCR,
assigning the signals for
PPARa/b-actin ratio in
unstimulated cells as 100 %, the
expression of PPARa for each
dose response treatment was
relative to this control value.
Effect of inhibitors on the IL-6-
treated PPARa mRNA
suppression was statistically
analyzed by one-way analysis of
variation (ANOVA). Statistical
significance (*P \ 0.05,
**P \ 0.01, and ***P \ 0.001)
is indicated above bar
R
E
V
IS
E
D
PR
O
O
F
when the cells were treated with IL-6. Interestingly, pre-
treatment with AG490 at 500 lM almost abolished the
suppression caused by IL-6 by increasing the transcrip-
tional activity of the PPARa promoter by 25 %, suggesting
the involvement of the JAK2–STAT1/3 pathway in medi-
ating the suppression of IL-6-mediated PPARa gene tran-
scription (Fig. 3). The inhibitors used to elucidate the
PI3K/AKT/mTOR pathway increased the PPARa promoter
activities to 20, 10, and 6 % when IL-6-treated cells were
preincubated with wortmannin, AKTIV, and rapamycin,
respectively. However, it should be noted that only wort-
mannin (20 % induction) attained significance. The inhi-
bition of IL-6-induced suppression of PPARa promoter
activity by the inhibitors wortmannin, AKTIV, and rapa-
mycin strongly suggests that the PI3K–AKT–mTOR
pathway may be responsible in mediating the inhibitory
effects of IL-6 on PPARa promoter activity. This pattern of
attenuation also indicates that the wortmannin inhibitor at
the upstream cascade blocked the IL-6 suppression on the
PPARa promoter activity more effectively than the inhib-
itor used at the downstream cascade of PI3K pathway.
The STAT-binding site in PPARa promoter (from
-612 to -604) is responsible for IL-6 suppression
of PPARa activity
The role of JAK2–STAT1/3 pathway may indicate a piv-
otal role for STAT in modulating the activity of PPARa
promoter by IL-6. In addition, scanning the PPARa pro-
moter using MatInspector [43] revealed the presence of a
potential binding site for STAT transcription factor located
between nucleotides -612 and -604 (Fig. 4a). In order to
determine the importance of the STAT site, we transiently
transfected HepG2 cells with wt PPARa promoter (-765/
?34) or with STATmut PPARa promoter which had three
nucleotides altered within the predicted STAT-binding site
(Fig. 4a). The STAT site was mutated according to Yu
et al. [44], which abolished unwanted binding sites for the
other transcription factors and completely abrogates
STAT-binding activity. The mutations (muts) of STAT-
binding site almost abolished the suppression induced by
IL-6 on the PPARa promoter activity (Fig. 4b). In addition,
cotransfection with STAT1 and STAT3 expression plas-
mids in untreated HepG2 cells significantly reduced the
transcriptional activities of the PPARa promoter and the
control to 82 and 90 %, respectively (Fig. 4c). Thus, these
results clearly demonstrate the role of STAT-binding site
present in the PPARa promoter in mediating the IL-6
inhibition of PPARa gene expression.
In order to determine that down-regulation of PPARa by
IL-6 was indeed mediated by the bindings of STAT1 and
STAT3 transcription factors to the STAT-binding site
Fig. 3 Effects of AG490, wortmannin, AKTIV, and rapamycin on
IL-6-mediated suppression of PPARa promoter activity. HepG2 cells
were transfected with luciferase reporter construct containing the
promoter of PPARa gene (-765/?34) in the absence and the
presence of IL-6. The transient-transfected cells were then pretreated
with AG490, wortmannin, AKTIV, and rapamycin for 2 h before
treatment with 1,000 U/ml of IL-6 for 24 h. Relative induction (%) of
the promoter constructs activities in IL-6-treated cells inhibitors and
without treatment of individual inhibitors, compared with untreated
cells (control) which has been assigned as 100 %
Fig. 4 STAT-binding site in PPARa promoter played a significant
role in IL-6 suppression of PPARa activity. a Identification of the cis-
acting element responsible for IL-6 response on PPARa gene
expression. The predicted STAT-binding site on PPARa promoter
(-765/?34) is shown in box and the mutated nucleotides within
STAT-binding site is indicated in bold. b Relative induction (%) of
the effect of mutations in the STAT-binding sites on IL-6-regulated
PPARa promoter activities. c The influence of STAT1 and STAT3
expression plasmids on PPARa promoter. HepG2 cells were
cotransfected with the (B2) PPARa promoter luciferase constructs
(-765/?34), along with 2 lg STAT1 and STAT3 expression
plasmids. The fragments without IL-6 treatment have been assigned
as 100 % and the values of their respective fragments in cells treated
with IL-6 being shown in relative to the control value
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(-612 to -604), we examined the interaction of nuclear
extracts, prepared from HepG2 cells treated with IL-6 over
the period of 120 min. EMSA showed three major DNA–
protein complexes designated as C1–C3 that were present
in the untreated cells, with IL-6-treated nuclear extracts
producing a significant induction in the DNA–protein
complexes C2 and C3 at 15 and 30 min, respectively
(Fig. 5a). The specificities of complexes C2 and C3 were
confirmed when these complexes were competed out using
4009 of unlabeled STAT oligonucleotides (Fig. 5b).
Complex C1 may represent a nonspecific interaction as the
complex was not competed out by unlabeled oligonucleo-
tides. Unlabeled STAT wild-type oligonucleotides
(STATwt) completely abolished the formation of com-
plexes C2 and C3 (Fig. 5c) and is consistent with Fig. 5b.
Cold competition using the unlabeled STAT containing
mutations (STATmut) binding site showed no effect on the
formation of complexes C2 and C3, which strongly indi-
cated that C2 and C3 represented specific interactions of
proteins to STAT binding (Fig. 5c). We then confirmed
that the complexes C2 and C3 contained STAT proteins by
performing SS analysis using antibodies for STAT1 and
STAT3 in EMSA. The incubation with antibodies against
STAT1 and STAT3 produced an inhibition in the mobility
of complexes C2 and C3, resulting in a formation of new
supershifted complexes, SS1 and SS2 (Fig. 6a). Specifi-
cally, both antibodies partially reduced the formation of
complex C3 and completely abolished the presence of
complex C2. In contrast, complex C1 was not affected by
antibodies against STAT1 and STAT3. These results sug-
gest that STAT1 and STAT3 participated in the DNA–
protein interactions which mediated the IL-6-inhibition of
the PPARa promoter transcriptional activity. Interestingly,
these results may also suggest that STAT1 and STAT3
proteins may form homo- and heterodimer between
themselves.
STAT1 and STAT3 are responsible in mediating the IL-
6-induced suppression of PPARa expression through
JAK–STAT and PI3K pathways
To substantiate that an increase in the formation of com-
plexes C2 and C3 was mediated through JAK2–STAT1/3
pathway, EMSA was performed using nuclear extracts
from cells pretreated with 500 lM of AG490. As expected,
the formation of complexes C2 and C3 was induced upon
IL-6 stimulation compared with the untreated nuclear
extract cells (Fig. 6b). The formation of these complexes
was almost abolished when cells were pretreated with
AG490 (Fig. 6b), corresponding to the inhibition of the
phosphorylation of tyrosine residue of STAT1 and STAT3
and attenuated effect on the inhibitory action of IL-6 on
PPARa expression levels. These results suggest that the
binding of STAT1 and STAT3 is essential for mediating
the IL-6-induced suppression effect on PPARa expression
via JAK2–STAT1/3 pathway in HepG2 cells. We also
investigated the connection of STAT-binding activity in
the downstream PI3K pathway when induced by IL-6 using
rapamycin to block the STAT activation. Interestingly,
rapamycin was found to inhibit the binding activity of
STAT proteins to the labeled STAT oligonucleotides,
thereby reducing the formation of complexes C2 and C3
(Fig. 6c). These results strongly indicate that the formation
of complexes C2 and C3 was also regulated by PI3K
activation, confirming the role of PI3K in IL-6-induced
STAT phosphorylation and STAT-binding activity.
Fig. 5 Analysis of the DNA-binding proteins to the STAT-binding
site of PPARa promoter. a Time course of DNA-binding proteins to
the STAT-binding site of PPARa promoter in response to IL-6
treatment. HepG2 cells were either untreated or treated with 1,000
U/ml of IL-6 for 15, 30, 45, 60, and 120 min. Nuclear extracts were
then isolated, and 20 lg of nuclear extract was subjected to EMSA
using biotin-labeled STAT (-612/-604) oligonucleotides. C repre-
sents patterns of DNA–protein complexes (C1–C3) detected, indi-
cated by labeled arrows. b Analysis of the binding specificity of
DNA–protein interactions in EMSA. Competition EMSA was carried
out using nuclear extracts (20 lg) from IL-6-treated HepG2 cells, in
the presence of 1009, 2009, 3009, and 4009 molar excesses of
unlabeled STAT-binding site oligonucleotides containing correspond-
ing sequence of human STAT-binding site. c Competition experi-
ments using mutated STAT oligonucleotides. Cold competition
experiments were performed with labeled STAT-binding site oligo-
nucleotides against unlabeled wild-type (STATwt) and labeled
STAT-binding-site oligonucleotides against unlabeled STAT con-
taining mutations (STATmut) at positions -607, -608, and -610
within the STAT recognition element (nucleotides from -612 to
-604)
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Discussion
APR is a short-term response which is important in
maintaining normal physiological homeostasis to counter-
act tissue injuries, infection, and trauma [45]. It is char-
acterized by drastic changes in the concentration of APPs
in the liver in response to activators [26], in which the
activator IL-6 plays a major role [26, 28, 46]. IL-6 cytokine
exerts its effect by binding to its receptor which is com-
posed of two subunits, an 80-kDa IL-6 binding protein of
mammalian cell surface and a 130-kDa transmembrane
signal transducing component (gp130; [47]). IL-6 drives
intracellular signaling pathways like JAK–STAT and
MAPKs and activates a wide variety of APP genes
including CRP, SAA, haptoglobin, fibrinogen, a1-acid gp,
a1-antichymotrypsin, and albumin [20, 26].
IL-6 acts via activating the regulators that directly
modulate the expression levels of APPs. Increasing evi-
dence suggests that PPARa plays an important role in the
development of APR, particularly in regulating the
expression levels of APPs [26]. However, detailed analyses
on the molecular mechanisms and pathways triggered by
IL-6 in regulating the expression of PPARa are limited.
The present study demonstrated that JAK–STAT and
PI3K pathways are involved in the STAT-mediated IL-6-
inhibition of PPARa expression in HepG2 cells treated
with IL-6. Four pieces of evidence from this study support
this notion. First, specific JAK–STAT and PI3K inhibitors
attenuated the mRNA and protein suppression of PPARa
by IL-6. Second, this study proposed that the PI3K–AKT–
mTOR pathway mediated the IL-6-inhibition of PPARa
expression and was associated with JAK2–STAT1/3 acti-
vation. Third, the inhibitors of JAK–STAT and PI3K
individually attenuated the IL-6-induced suppression on
PPARa promoter activity in transient transfection assay.
Finally, IL-6-inhibition of PPARa expression at the tran-
scriptional level was regulated via the STAT-binding site
of PPARa promoter.
We demonstrated for the first time that the signal
transduction pathways of JAK2–STAT1/3 and PI3K/AKT/
mTOR were responsible for mediating the inhibitory effect
of IL-6 on PPARa gene expression in HepG2 cells. These
results correspond with the previous studies reporting that
the signaling routes triggered by IL-6 to exert its effects in
liver mainly involved JAK–STAT [35, 48, 49] and PI3K
pathways [36, 50, 51]. Our study also revealed that the
activation of JAK2–STAT1/3 pathway by IL-6 depends
largely on the phosphorylation of tyrosine residues. Since
the JAK–STAT inhibitor, AG490, effectively inhibited the
IL-6-induced repression of PPARa mRNA, protein, and
promoter activity, it is likely that the IL-6-induced PPARa
suppression was mainly activated by Tyr701 STAT1 and
Tyr705 STAT3. Actually, accumulating evidence revealed
that phosphorylation of tyrosine kinase residue is a
Fig. 6 STAT1 and STAT3 are responsible for IL-6 suppression of
PPARa activity. a IL-6-induced direct STAT1 and STAT3 DNA-
binding protein of PPARa promoter to regulate the IL-6 suppression
of PPARa gene expression. EMSA SS analysis was used to determine
the presence of STAT1 and STAT3 proteins’ complexes. IL-6-treated
nuclear extracts (20 lg) from HepG2 cells were used for EMSA in the
absence of antibody (IL-6) or in the presence of anti-STAT antibodies
(STAT1 and STAT3). b The effects of AG490 on the IL-6-induced
STAT-binding activity. HepG2 cells were either untreated or
pretreated with AG490 for 2 h before treatment with 1,000 U/ml of
IL-6 for 30 min. Nuclear extracts were then isolated and subjected to
EMSA using biotin-labeled STAT oligonucleotides. c The effects of
rapamycin on the IL-6-induced STAT-binding activity. HepG2 cells
were either untreated or pretreated with rapamycin for 2 h before
treatment with 1,000 U/ml of IL-6 for 30 min. Nuclear extracts were
then isolated and subjected to EMSA using biotin-labeled STAT
oligonucleotides. The DNA–protein complexes are shown with
labeled arrows (C2 and C3), and the antibody SS band is as indicated.
The result is representative of three independent experimental series
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prerequisite for STAT activation by IL-6 [51, 52]. In
addition, APPs are regulated by IL-6 via the phosphory-
lation of tyrosine residues of STAT1 and STAT3, SHP2,
and gp130 [53].
It is well documented in IL-6-activated PI3K pathway
studies that PI3K protein is the first component activated,
which then responds to activate AKT, and subsequently
phosphorylates and regulates the activity of mTOR [54–
56]. In this study, we demonstrated that PI3K pathway
inhibited the IL-6-induced suppression of PPARa mRNA,
PPARa protein, and PPARa promoter activity with a PI3K
inhibitor and produced a higher attenuated effect followed
by the inhibitors for AKT and mTOR. The role of IL-6-
activated PI3K pathway in regulating the APPs is not well
established. However, there are studies demonstrating the
involvement of this pathway in the prosurvival, antiapo-
ptotic effect of IL-6 in protecting and regenerating the liver
cells [57–59].
Our finding also suggested a potential crosstalk between
JAK2–STAT1–3 and PI3K/AKT/mTOR in the activation
of STAT at the downstream level of the PI3K pathway. We
showed that AG490 and rapamycin abolished the STAT–
DNA-binding activity represented by complexes C2 and
C3 (Fig. 5b, c). In support of this discovery, these inhibi-
tors were also found to inhibit the quantity of activated
STAT isoforms present in STAT–DNA-binding activity
assays in other cell types [60, 61]. Therefore, it is tempting
to speculate that IL-6-induced suppression of PPARa gene
expression may also be mediated through the crosstalk
between PI3K/AKT/mTOR and JAK/STAT pathways by
inhibiting tyrosine phosphorylation of STAT1 and STAT3
and blocking STAT dimer formation to reduce STAT–
DNA-binding activity. Indeed, Tron et al. [48] reported that
the inhibition of PI3K pathway completely obliterated the
functional activity of STAT in inducing the heme oxy-
genase-1 gene by IL-6. In addition, a novel model has been
strongly suggested for mTOR effecting IL-6 signaling by
regulating STAT3 phosphorylation and activation [62].
Hence, this study supports the potential presence of a novel
crosstalk between the PI3K and STAT3 pathways (PI3K–
AKT–mTOR–STAT) to down-regulate PPARa mRNA
levels in response to IL-6. Concomitantly, studies have also
shown that STAT3 is phosphorylated and activated in a
PI3K-dependent manner in PI3K-transformed murine cells,
thus providing a promising therapeutic target that could
enhance the effectiveness of PI3K inhibitors [63].
STATs have been identified as a family of transcription
factors that play an important role in gene regulation in
response to cellular stimulation by growth factors (GFs)
and cytokines [47]. In addition, STAT1 and STAT3 were
also found to be activated by IL-6 in hepatocytes [64, 65].
Because of their size (90 kDa) that is far beyond the
exclusion limit of nuclear pore, STAT needs to be
phosphorylated and actively translocated into the nucleus
to regulate the expression of certain genes involved in APR
[66, 67]. As STAT is associated with other pathways and
also plays a critical role in controlling and mediating IL-6-
effects of APP genes, the STAT site in the human PPARa
gene promoter may also play a crucial role in mediating the
action of IL-6. Thus, the conventional mechanism of
phosphorylated STAT dimers bound to STAT-binding site
was proposed in this study. Transient transfection and
EMSA analyses using wt and mutated STAT-binding sites
on the PPARa promoter region (-765/?34) established
that the STAT-binding site within the promoter was
required for the interaction with STAT1 and STAT3 in
mediating the IL-6 suppressive response on PPARa gene
expression. Furthermore, cotransfection analysis of human
PPARa promoter with STAT1 and STAT3 expression
plasmids considerably reduced the constitutive expression
of PPARa, further suggesting that both STAT1 and STAT3
homo- or heterodimers may serve as repressors in PPARa
transcriptional activity. Although STAT was originally
identified as an activator of transcription [68–70], STAT1
and STAT3 have been implicated as repressors to a vast
number of genes [71–73]. For example, GF-activated
transcription of STAT5 and STAT3 was found to nega-
tively regulate the PPARa transcriptional activity in COS-1
cells [73]. In fact, other studies have shown that STATs
activated by IL-6, IL-1, IFN-c, and TNF-a have the ability
to down-regulate PPARc gene expressions [74–77]. Anti-
body SS assays further confirmed the interaction between
STAT1 and STAT3 with the STAT-binding site. However,
due to partial inhibition of complex C3 by antibodies,
STAT1 and STAT3 may also form heterodimers with other
STAT family members/transcription factors. For example,
phosphorylation of STAT-induced SH2-mediated hetero-
dimerization with STAT family members, followed by
translocation of the STAT dimer for transcription activa-
tion and subsequent binding to specific consensus sequence
of target-gene promoters in the nucleus [12, 47, 78]. Het-
erodimerization of STATs was achieved via reciprocal
binding of this critical, phosphorylated tyrosine of one
monomer, and SH2 domain of the partner dimer and were
frequently observed in cytokine responses [44, 70]. Thus,
our findings suggested that the effects of IL-6 suppression
on PPARa promoter were dependent on tyrosine phos-
phorylation of STAT1 and STAT3 and subsequently the
DNA-binding activity of STAT to its corresponding bind-
ing site via protein–protein interactions within the STAT
family members or/and with other transcription factors [73,
79]. Activations and DNA-binding activities of STAT1 and
STAT3 were increased reaching their peaks within
15–30 min after incubation with IL-6 (Fig. 5). Therefore, it
can be hypothesized that STAT1 and STAT3 proteins were
translocated to the nucleus within 15 min after the
R
E
V
IS
E
D
PR
O
O
F
treatment and were mostly deactivated after 2 h. These
parameters were consistent with STAT activation by IL-6
in other cell types [80, 81]. For example, the transient
binding of STAT protein to IL-RE of the a2-macroglobulin
promoter was demonstrated in rat ovary [80]. The induc-
tion pattern of STAT-binding activity also closely mirrored
the induction of phosphorylation of Tyr701 STAT1 and
Tyr705 STAT3. Since the binding activity of STAT
occurred at similar time points (15–30 min) as those of the
phosphorylation, it is tempting to speculate that the binding
activities of STAT1 and STAT3 to the PPARa promoter
were transient and mainly regulated by phosphorylation. In
agreement with this result, studies have shown that the
prerequisite for STAT transcriptional activities depends on
its phosphorylation resulting in dimerization which enables
nuclear localization and DNA binding [82]. The duration of
STAT phosphorylation, and therefore, the transcriptional
activity, is regulated by the balance of receptor-driven
JAK2 catalytic activity and constitutive nuclear dephos-
phorylation by a protein, tyrosine phosphatase [69, 83, 84].
Other studies demonstrated that the loss of phosphorylation
of tyrosine residue upon DNA binding in the nucleus
causes STAT protein to be transported back to the cyto-
plasm which may lead to the abolition of STAT activation
and binding activity [70, 78].
In summary, this study has successfully unraveled
pathways by which IL-6 inhibits PPARa gene transcrip-
tion, involving the modulation of JAK2–STAT1/3 and
PI3K–AKT–mTOR pathways, as well as a possible cross-
talk between PI3K–AKT–mTOR and STAT pathways. The
present study also underlines the significance of JAK–
STAT as a dominant pathway due to crosstalks between
JAK–STAT and PI3K via JAK activation and STAT
transcription factors in down-regulating the PPARa mRNA
expression. Altogether, these findings represent a new
model of IL-6-induced suppression of PPARa expression.
Accordingly, given that the PPARs play a major role as
lipid-sensing transcription factors that regulate cholesterol
and fatty acid homeostasis [23–25] and the emerging evi-
dence that this transcription factor family is also implicated
in the development of APR in the liver and inflammation
and atherosclerosis [25–29], future studies are essential to
delineate the role of PPAR in the development of APR.
Although our studies were focused on PPARa in a liver
cell culture model; determining which regulatory pathways
are activated by PPARa may have therapeutic implications
and may help clarify whether targeting these pathways is
an effective approach in the management of inoperable or
recurrent APR.
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